Drugs / TQ Formula
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04914377 | Jun → Dec 2021 | COVID-19 | Novatek Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQ Formula | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04914377 ↗ |
| Route | Oral | “TQ Formula (Nigella Sativa) 500 mg, 3 capsules, BID, taken orally” NCT04914377 ↗ |